Viz.ai Viz Aneurysm Software
Viz.ai Viz Aneurysm Software [Image courtesy of Viz.ai]
Category: Health, Medical and Biotech
Subcategory: AI-Assisted Medicine
From the winners: “Viz Aneurysm, the first fully-automated AI algorithm to receive FDA-clearance, detects suspected cerebral aneurysms, which can potentially rupture if not actively monitored. Mobile, HIPAA-compliant communication tools ensure that the aneurysm workflow across the entire health system is standardized, so more patients get neurovascular follow-up.”
“We gathered input on Viz Aneurysm by partnering closely with our advisors and clinicians in an interactive R&D process to refine user needs into novel product design. Viz.ai has formed a Physician Advisory Board, which provides strategic advice regarding emerging science and therapeutic trends, informs R&D decisions, and ensures that sound scientific evidence supports projects. Post-launch, we continue to work with clinical teams on workflow implementation and optimization, since care pathways need to be tailored to each team and hospital system as well as their systems and processes.”
“The quality of the AI algorithm and integration of AI-powered detection and mobile communication tools redefine care pathways for patients with suspected cerebral aneurysms. A University of Toronto study tested the accuracy of Viz Aneurysm using 528 computed tomography angiographies (CTAs) with 674 aneurysms distributed across the cerebral vascular territories. Analysis demonstrated 94% accuracy for the algorithm. Furthermore, clinicians can access high-fidelity images anywhere and anytime. Viz’ HIPAA-compliant, text messaging and calling platform empowers clinical teams to coordinate care and treatment decisions across a hospital network.”
